Skip to content
About
Acer Management
Board of Directors
Key Strategic Consultants
Scientific Advisory Board
Careers
Pipeline
ACER-001 for UCDs
ACER-001 for MSUD
ACER-801 for iVMS
EDSIVO™ for vEDS
ACER-2820 for Infectious Diseases
Patients & Physicians
Patient Advocacy
Publications
Urea Cycle Disorders (UCDs)
Maple Syrup Urine Disease (MSUD)
Induced Vasomotor Symptoms (iVMS)
Vascular Ehlers-Danlos Syndrome (vEDS)
Infectious Diseases
Expanded Access
Investor Relations
Press Releases
Events & Presentations
SEC Filings
Analyst Coverage
Stock Information
Corporate Governance
Investor FAQs
Contact Us
About
Pipeline
Investor Relations
Publications
Contact Us
Investor FAQs
Analyst Coverage
Corporate Governance
Stock Information
Events & Presentations
About
Pipeline
Investor Relations
Publications
Contact Us
SEC Filings
Investor Relations
QUICK
NAV
MENU
MENU
About
Acer Management
Board of Directors
Key Strategic Consultants
Scientific Advisory Board
Careers
Pipeline
ACER-001 for UCD
ACER-001 for MSUD
ACER-801 for iVMS
EDSIVO™ for vEDS
ACER-2820 for Infectious Diseases
Patients & Physicians
Patient Advocacy
Publications
Urea Cycle Disorders (UCDs)
Maple Syrup Urine Disease (MSUD)
Induced Vasomotor Symptoms (iVMS)
Vascular Ehlers-Danlos Syndrome (vEDS)
Infectious Diseases
Expanded Access
Investor Relations
Press Releases
Events & Presentations
SEC Filings
Analyst Coverage
Stock Information
Corporate Governance
Investor FAQs
Contact Us
